美團點評(3690.HK)漲超6%再創歷史新高 市值超1.25萬億升至港股第6位
格隆匯8月4日丨入選了格隆匯2020年“下注中國十大核心資產”名單的美團點評(3690.HK)今日繼續上漲盤中再創歷史新高價214.6港元,半日收漲6.28%報213.2港元,成交41.8億港元,最新總市值1.253萬億港元。市值超農業銀行升至港股市場第6位,僅次於阿里、騰訊、工行、平安和建行。自今年3月19日低點至今,該股已累漲206%。恆生指數有限公司此前推出恆生科技指數,美團點評(3690.HK)獲納入並於7月27日正式生效,被納入後至今美團已累漲16%。據格隆匯APP數據顯示,南下資金自7月28日至今連續5日淨買入該股共計22.81億港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.